Medasense
HealthTech & Life SciencesMedasense develops monitoring technology for assessing physiological responses to painful stimulation during anaesthesia, giving clinical teams additional information alongside existing monitoring.
Introduce me to Medasense
Founders & company facts
Sources reviewed:Reported cumulative funding
$32,500,000 · Source
This index includes companies with publicly reported total funding up to US$150 million. This is a reported total, not valuation, the latest round size or confirmation of an open round. Funding reviewed: .
Documented founding team
No confirmed founder names are included in this profile.
- Founded
- Not confirmed
- Reported Israeli location
- Not confirmed
- Team range in directory
- Not confirmed
- Reported business model
- Not confirmed
Selected disclosed financing
Selected transactions, with dates, funding types and reported participants.
Individual financing rounds have not been documented in this profile. A reported total is shown above when available.
Company overview
Product & customers
Medasense develops monitoring technology for assessing physiological responses to painful stimulation during anaesthesia, giving clinical teams additional information alongside existing monitoring.
Commercial potential · editorial analysis
For Medasense, the commercial question is how nociception monitoring supports paying customers over time. The opportunity involves fitting a clearly defined use case into an existing care or wellbeing workflow. A review should distinguish trials from paid adoption and examine the support and delivery work required as usage expands.
What to validate
When assessing Medasense, diligence should cover the intended use, appropriate clinical evidence, accessibility, privacy and the approval status required for the target market. Prospective users should ask for evidence from settings comparable to their own, including unsuccessful cases and costs, before drawing conclusions about deployment suitability.
Product source reviewed on . Company source